Pharmala Biotech Holdings Inc

Pharmala Biotech: Canadian biotech focused on oncology drug discovery and commercialization, offering breakthrough therapies and strategic partnerships to improve patient outcomes.

Pharmala Biotech: Canadian biotech leader in oncology, innovating breakthrough cancer therapies, strong R&D pipeline, and strategic collaborations for patient‑centric impact.

Pharmala Biotech’s successful release testing of its first Australian LaNeo MDMA 40 mg batch marks a major production milestone, boosting its oncology pipeline and global growth plans.

Pharmala Biotech: Canadian oncology‑focused biotech driving breakthrough cancer therapies, building IP, partnerships, and sustainable growth for patient outcomes.

Pharmala Biotech Holdings Inc (PHLM) is a tiny Canadian biotech focused on oncology, trading at CAD 0.10 with a CAD 12 m market cap and a negative P/E—an overview of its precarious finances and high‑risk investment profile for speculative traders.

Pharmala Biotech’s oncology‑focused R&D and commercial partnerships are driving breakthrough cancer therapies, boosting investor confidence despite a low stock price.

Pharmala Biotech Holdings: oncology‑focused Canadian biotech with strong R&D and partnership plans, yet facing cash‑burn and volatility; investors weigh potential breakthroughs versus financial risk.

Pharmala Biotech Holdings Inc., a Canadian biotechnology firm, is making significant strides in the biopharmaceutical industry through its innovative therapeutic agents and strategic partnerships, positioning it for future growth and success in the …

Pharmala Biotech Holdings Inc. has incorporated a new Australian entity, PharmAla Biotech Australia Pty Ltd., to bolster its clinical research capabilities and accelerate the development of its proprietary therapeutic agents, particularly in the fie…

Pharmala Biotech Holdings Inc. is a Canadian biotech company pioneering innovative cancer therapies through its robust research and development efforts, strategic partnerships, and commitment to delivering transformative patient outcomes.